Filter zurücksetzen
Stichworte
AML ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

269 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Autologous Transplant Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Autologous Transplant Form

- 11.02.16 - 1 Formular, 4 Itemgruppen, 14 Datenelemente, 1 Sprache
Itemgruppen: Conditioning, Drug, Transplant, Comments
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Form Description: Autologous Transplant Form

Rapid Reporting Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Rapid Reporting Form

- 11.02.16 - 1 Formular, 5 Itemgruppen, 21 Datenelemente, 1 Sprache
Itemgruppen: Form Relation, Treatment, Survival Status, Toxicity, Recovery
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Form Description: Rapid Reporting Form

Tissue Typing Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Tissue Typing Form

- 11.02.16 - 1 Formular, 5 Itemgruppen, 34 Datenelemente, 1 Sprache
Itemgruppen: Tissue Typing Form, Allo HSCT, HLA Patient, HLA Donor, Comments
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Form Description: Tissue Typing Form

Cycle AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Cycle AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 11.02.16 - 1 Formular, 15 Itemgruppen, 60 Datenelemente, 1 Sprache
Itemgruppen: At start of cylce, For Induction I only, Cycle, Cytarabine, Daunorubicin, Dasatinib, Events, Inpatient Hospitalisation during Cycle, MUGA/Echo Scan, Concomitant Medication, Buccal Swab (For Induction I only), Pregnancy test, Supportive Care, Hematological Regeneration, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

End of Study AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - End of Study AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 11.02.16 - 1 Formular, 2 Itemgruppen, 13 Datenelemente, 1 Sprache
Itemgruppen: End of Study, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Internal Follow-up Akute myeloische Leukämie (AML) Department of Internal Medicine Knappschaftskrankenhaus Bochum-Langendreer - Internal Follow-up KKH Akute myeloische Leukämie (AML)

- 11.02.16 - 1 Formular, 1 Itemgruppe, 42 Datenelemente, 1 Sprache
Itemgruppe: Patient data
Data derived from paper-based form of the Department of Internal Medicine. With friendly permission of Prof. Dr. med. Schmiegel and Prof. Dr. med. Schroers http://www.medunikkh.de/

Baseline Concomitant Diseases Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Baseline Concomitant Diseases Form

- 11.02.16 - 1 Formular, 1 Itemgruppe, 5 Datenelemente, 1 Sprache
Itemgruppe: Baseline Concomitant Diseases
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Description of Form: Baseline Concomitant Diseases Form

M6 Bone Marrow Evaluation Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - M6 Bone Marrow Evaluation Form

- 11.02.16 - 1 Formular, 2 Itemgruppen, 20 Datenelemente, 1 Sprache
Itemgruppen: Bone Marrow Evaluation, Comment
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Description of Form: M6 Bone Marrow Evaluation Form

Hematological Evaluation Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Hematological Evaluation Form

- 11.02.16 - 1 Formular, 3 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Form Relation, Supportive Care, Hematological Evaluations
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Description of Form: Hematological Evaluation Form

Pregnancy Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Pregnancy Form

- 11.02.16 - 1 Formular, 4 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Site Information, Subject Information, Trial Medication and Outcome, Comments
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Description of Form: Pregnancy Form

Adverse Event Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Adverse Event Form

- 11.02.16 - 1 Formular, 1 Itemgruppe, 11 Datenelemente, 1 Sprache
Itemgruppe: Adverse Event
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) Description of Form: Adverse Event Form

Hematology / Clinical Chemistry AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Hematology / Clinical Chemistry AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 11.02.16 - 1 Formular, 5 Itemgruppen, 29 Datenelemente, 1 Sprache
Itemgruppen: Point in time, Hematology, Clinical Chemistry, Coagulation, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video